UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 3, 2016

 

PRA Health Sciences, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36732

 

46-3640387

(State or Other
Jurisdiction of Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

4130 ParkLake Avenue

Suite 400

Raleigh, NC 27612

(919) 786-8200

(Address, including zip code, and telephone number,

including area code, of registrant’s principal executive offices)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01.                                        Other Events.

 

On March 3, 2016, PRA Holdings , Inc., a subsidiary of PRA Health Sciences, Inc., issued a press release to announce preliminary results of its previously announced tender offer (the “Tender Offer”) to purchase for cash up to $75.0 million aggregate principal amount (the “Maximum Tender Amount”) of its 9.500% Senior Notes due October 1, 2023. PRA Holdings, Inc. also announced that it has increased the Maximum Tender Amount for the notes in the Tender Offer from $75,000,000 to $133,559,000. A copy of the press release related to the Tender Offer is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

Item 9.01                                           Financial Statements and Exhibits.

 

(d)                                 Exhibits.

 

See the Exhibit Index immediately following the signature page hereto, which is incorporated herein by reference.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PRA Health Sciences, Inc.

 

 

 

Date: March 7, 2016

 

 

 

By:

/s/ Timothy McClain

 

Name:

Timothy McClain

 

Title:

Vice President of Legal Affairs and Assistant Secretary

 

3


 

EXHIBIT INDEX

 

99.1                                                Press Release, dated March 3, 2016

 

4